Table 1.
Comparison of demographic and clinical characteristics between TN patients and healthy controls (HC), as well as within TN patients (responders vs. non-responders)
| Responders | Non-Responders |
P-value (2-tailed) |
TN | HC | P-value (2-tailed) | |
|---|---|---|---|---|---|---|
| Total # | 17 | 6 | - | 23 | 20 | - |
| Sex (Female/Male) | 8/9 | 6/0 | 0.048* | 14/9 | 11/9 | 0.70 |
| Age (years) | 58.6 9.7 | 47.4 10.3 | 0.016* | 56.3 10.4 | 54.9 9.4 | 0.65 |
| Duration of TN (years) | 4.6 3.3 | 8.8 4.7 | 0.061 | 5.3 3.9 | N/A | - |
| Side of pain (left/right) | 6/11 | 2/4 | > 0.99 | 8/15 | N/A | - |
| Pre-op VAS (mm) | 79.9 24.1 | 66.8 38.7 | 0.50 | 77.6 27.3 | N/A | - |
| NVC (yes/no) | 14/3 | 3/3 | 0.27 | 17/6 | N/A | - |
| NVC score (0/1/2/3) | 3/3/6/5 | 3/0/2/1 | 0.64 | 6/3/8/6 | N/A | - |
| Virgin (yes/no) | 14/3 | 3/3 | 0.28 | 17/6 | N/A | - |
| Surgery type (MVD/BC) | 13/4 | 3/3 | 0.32 | 16/7 | N/A | - |
|
Carbamazepine/ oxcarbazepine (yes/no) |
15/2 | 6/0 | > 0.99 | 21/2 | N/A | - |
| Gabapentin/pregabalin (yes/no) | 7/10 | 5/1 | 0.16 | 12/11 | N/A | - |
| Other antiepileptics (yes/no) | 2/15 | 1/5 | > 0.99 | 3/20 | N/A | - |
| Antidepressant (yes/no) | 2/15 | 1/5 | > 0.99 | 3/20 | N/A | - |
| Baclofen (yes/no) | 2/15 | 4/2 | 0.021* | 6/17 | N/A | - |
| Opioid (yes/no) | 0/17 | 1/5 | 0.26 | 1/22 | N/A | - |
| Cannabis oil (yes/no) | 1/16 | 1/5 | 0.46 | 2/21 | N/A | - |
Mann Whitney, and Chi-square or Fisher’s-exact tests used where appropriate. Means standard deviations are presented. NVC (yes/no): neurovascular compression; NVC score (0/1/2/3)[23]: degree of neurovascular compression; Virgin (yes/no): first-time surgical treatment for TN; MVD microvascular decompression; BC balloon compression rhizotomy; other antiepileptics: lamotrigine, topiramate; antidepressant: amitriptyline, duloxetine.